<DOC>
	<DOCNO>NCT00017225</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . Combining therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy radiation therapy without peripheral stem cell transplantation treat patient neuroblastoma .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy With Without Peripheral Stem Cell Transplantation Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency spontaneous remission pediatric patient localize neuroblastoma . - Determine course regression patient spontaneous remission . - Determine event-free survival rate patient high-risk neuroblastoma treated maintenance chemotherapy OR consolidation chemotherapy follow autologous stem cell rescue . - Determine correlation exist long-term overall survival catecholamine response high-risk patient . - Determine correlation exist cytotoxic condition chemotherapy , term bone marrow toxicity , high-risk patient . OUTLINE : This multicenter study . Patients stratify accord risk ( low vs standard v high ) . - Observation stratum ( low risk ) : Patients undergo surgical biopsy follow observation 6-12 month . Patients may also undergo second-look surgery . Patients tumor regression receive therapy . Patients disease progression tumor regression receive standard-risk chemotherapy standard-risk stratum . - Standard-risk stratum : Patients undergo surgical biopsy . Patients least 6 month age receive 1 course chemotherapy comprise cisplatin IV etoposide IV continuously day 1-4 vindesine IV 1 hour day 1 . Patients receive 1 course chemotherapy comprise vincristine IV 1 hour day 1 8 , dacarbazine IV 1 hour day 1-5 , ifosfamide IV continuously day 1-5 , doxorubicin IV 4 hour day 6 7 . Patients 6 month age receive doxorubicin IV 30 minute vincristine IV day 1 , 3 , 5 cyclophosphamide IV 5 minute day 1-7 . Treatment repeat every 3 week 2 course absence unacceptable toxicity . After chemotherapy , patient may undergo second-look surgery follow 2 additional course chemotherapy . Patients complete response good partial response receive therapy . Patients partial response , minimal response , response , progressive disease undergo local radiotherapy daily 5 day week approximately 6 week . Patients response radiotherapy may receive therapy high-risk stratum . - High-risk stratum : Patients undergo surgical biopsy . Patients least 6 month age receive induction chemotherapy comprise cisplatin , etoposide , vindesine standard-risk stratum combine filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 8 continue blood count recover . Patients also receive alternate course vincristine , dacarbazine , ifosfamide , doxorubicin standard-risk stratum combine G-CSF SC daily begin day 9 continue blood count recover . Treatment repeat every 3 week 6 course absence unacceptable toxicity . Patients 6 month age receive 2 course induction chemotherapy standard-risk stratum follow 4 course alternate chemotherapy . Patients may also undergo second-look surgery . Patients receive consolidation chemotherapy comprise melphalan IV 30 minute day -8 -5 , etoposide IV 4 hour day -4 , carboplatin IV 1 hour day -4 -2 . Patients undergo autologous stem cell transplantation ( ASCT ) day 0 . Patients also receive G-CSF SC IV 2 hour daily begin day 0 . Patients may undergo radiotherapy daily 5 day week 6 week . Patients diagnose less 1 year ago demonstrate MYCN amplication receive maintenance chemotherapy comprise oral cyclophosphamide day 1-8 ( instead consolidation chemotherapy ASCT ) . Treatment repeat every 3 week 4 course . Beginning 4-6 week transplantation 4 week initiation last course maintenance chemotherapy , patient receive consolidation therapy oral tretinoin 3 time daily day 1-14 . Treatment repeat every 28 day 6 course follow 3-month rest . Patients receive 3 additional course . Patients follow 6 week , every 3 month 5 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 130 patient ( 50 high-risk stratum , 15 standard-risk stratum , 65 observation stratum ) accrue study within 1 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm neuroblastoma Observation stratum : MYCN gene amplify Infants stage IIVS disease OR Over 1 year age stage I II resectable disease Standardrisk stratum : MYCN gene amplify Infants serious symptom stage IIIVS disease OR Over 1 year age stage II III unresectable disease Highrisk stratum : Stage IV disease OR Stage IIVS MYCN geneamplified disease PATIENT CHARACTERISTICS : Age : 20 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : No kidney insufficiency Cardiovascular : No cardiac insufficiency Other : Not pregnant Fertile patient must use effective contraception No serious illness PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy within 6 month diagnosis Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>